GeneTether Therapeutics (XCNQ:GTTX) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics COGS-to-Revenue?

GeneTether Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.00 Mil. Its Revenue for the three months ended in Dec. 2023 was C$0.00 Mil.

GeneTether Therapeutics's COGS to Revenue for the three months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. GeneTether Therapeutics's Gross Margin % for the three months ended in Dec. 2023 was N/A%.

GeneTether Therapeutics COGS-to-Revenue Historical Data

The historical data trend for GeneTether Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics COGS-to-Revenue Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial								-	-	-	-	-

GeneTether Therapeutics COGS-to-Revenue Calculation

GeneTether Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

GeneTether Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

GeneTether Therapeutics (XCNQ:GTTX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

GeneTether Therapeutics's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

GeneTether Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines